Cavinton Comfort, dispersible pills 10mg 90pcs

Composition

1 tablet contains

Active ingredients:

vinpocetine – 10 mg.

Auxiliary substances:

mannitol – 75.6 mg,

corn starch pregelatinization – 38 mg

of butylmethacrylate copolymer – 9 mg

of hyprolose viscosimetry 8 mg,

crospovidone 8 mg,

magnesium stearate – 2.85 mg

of sodium fumarate – 2.8 mg,

silicon dioxide colloid – 1.6 mg,

aspartame – 1.28 mg,

stearic acid – 1.26 mg,

sodium lauryl sulfate – 0.9 mg,

Dimethicone – 0.39 mg,

orange flavor – 0.32 mg.

Pharmacological action

A remedy that improves cerebral circulation and brain metabolism. Inhibits the activity of phosphodiesterase, which contributes to the accumulation of cAMP in the tissues. It has a vasodilating effect mainly on the vessels of the brain, which is due to a direct myotropic antispasmodic effect.

Systemic blood pressure decreases slightly. It improves blood supply and microcirculation in brain tissues, reduces platelet aggregation, and helps normalize the rheological properties of blood.

Improves the tolerance of hypoxia by brain cells, promoting the transport of oxygen to tissues due to a decrease in the affinity of red blood cells for it, increasing the absorption and metabolism of glucose. Increases the content of catecholamines in brain tissues.

Pharmacokinetics

When taken orally, it is rapidly absorbed from the gastrointestinal tract. _cmax in blood plasma is reached in approximately 1 h. With parenteral use, Vd is 5.3 l/kg. T_1/2 is about 5 hours.

Indications

Cerebrovascular disease (including stroke, vertebral-basilar insufficiency, brain injury, atherosclerotic changes of the vessels of the brain, vascular dementia, post-traumatic and hypertensive encephalopathy), intermittent failure, and spasm of cerebral vessels;

partial occlusion of the arteries, headache, dizziness (including the labyrinthine origin), memory impairment, movement disorders, including apraxia, aphasia, and arteriolosclerosis angiopathies changes in the retina and choroid, arterial and venous thrombosis of the vessels of the eye, degenerative changes in the yellow spot, secondary glaucoma due to obstruction of blood vessels;

age, vascular or toxic (medical) hearing loss, Meniere’s disease, cochleovestibular neuritis, tinnitus;

vasovegetative manifestations of a menopausal syndrome (in combination with hormonal therapy).

Contraindications

Hypersensitivity, severe forms of coronary heart disease and arrhythmias, the first days after a cerebral hemorrhagic stroke, increased intracranial pressure; pregnancy, breast-feeding.

Side effects

From the nervous system and sensory organs: dizziness, headache, insomnia, drowsiness, weakness.

From the cardiovascular system and blood (hematopoiesis, hemostasis): slowing of intraventricular conduction; ST segment depression and prolongation of the QT interval, hypotension, tachycardia, extrasystole, skin redness, thrombophlebitis at the injection site.

From the digestive tract: dry mouth, nausea, heartburn.

Skin disorders: sweating.

Other: allergic reactions.

Interaction

When used concomitantly with warfarin, a slight decrease in the anticoagulant effect of warfarin has been reported.

With simultaneous parenteral use of vinpocetine and heparin, the risk of bleeding may increase.

How to take, course of use and dosage

Individually.

For oral use-5-10 mg 3 times / day.

Special instructions

It is not recommended to prescribe with labile blood pressure and low vascular tone.

Caution should be exercised in patients taking antihypertensive medications or medications that increase the QT interval, as well as in patients with poor tolerance to Vinca minor alkaloids and suffering from liver failure.

Subcutaneous, intravenous, and jet intravenous use is not allowed.

It should not be used during work for drivers of vehicles and people whose profession is associated with increased concentration of attention.

When parenterally administered to patients with diabetes mellitus, it is necessary to control the blood glucose content (the solution contains sorbitol). In the presence of prolonged QT syndrome or with the simultaneous use of drugs that provoke prolongation of the QT interval, ECG monitoring is necessary.

In hemorrhagic stroke, parenteral use of the drug is permissible only after the acute events disappear (after 5-7 days).

There are not enough observations on the use of the drug in children’s practice.

Form of production

Dispersible tablets of white or almost white color, round, biconvex, with the inscription “N83” on one side.

Storage conditions

In a dark place, at a temperature of 15-30 °C.

Active ingredient

Vinpocetine

Conditions of release from pharmacies

By prescription

Dosage form

resorption tablets